NovoCure (NVCR) Operating Income Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -3.76% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 8.39% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 1.70% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 25.88% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 7.13% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 34.83% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 75.54% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -2.70% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | -24.91% |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | -3.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.82% |
| Dec 31, 2025 | 2.05% |
| Sep 30, 2025 | -13.54% |
| Jun 30, 2025 | -23.21% |
| Mar 31, 2025 | -260.83% |
| Dec 31, 2024 | -39.34% |
| Sep 30, 2024 | -55.40% |
| Jun 30, 2024 | -39.78% |
| Mar 31, 2024 | -678.50% |
| Dec 31, 2023 | -84.47% |
| Sep 30, 2023 | -80.46% |
| Jun 30, 2023 | -125.04% |
| Mar 31, 2023 | -161.20% |
| Dec 31, 2022 | -556.47% |
| Sep 30, 2022 | -103.15% |
| Jun 30, 2022 | -169.92% |
| Mar 31, 2022 | 49.12% |
| Dec 31, 2021 | -39.26% |
| Sep 30, 2021 | -17.69% |
| Jun 30, 2021 | -20.17% |
| Mar 31, 2021 | 80.92% |
| Dec 31, 2020 | 67.31% |
| Sep 30, 2020 | 65.56% |
| Jun 30, 2020 | 34.43% |
| Mar 31, 2020 | 36.77% |
| Dec 31, 2019 | 26.17% |
| Sep 30, 2019 | 28.79% |
| Jun 30, 2019 | 26.66% |
| Mar 31, 2019 | 42.35% |
| Dec 31, 2018 | 34.34% |
| Sep 30, 2018 | 39.96% |
| Jun 30, 2018 | 36.14% |
| Mar 31, 2018 | 16.72% |
| Dec 31, 2017 | 41.93% |
| Sep 30, 2017 | 30.86% |